This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Study Type
OBSERVATIONAL
Enrollment
5,000
overall survival from eligibility
Time frame: 15 years
Overall survival from administration
Time frame: 15 years
complete response rate
Time frame: 15 years
Progression free survival
Time frame: 15 years
Duration of response
Time frame: 15 years
Delays between patient eligibility and CAR-T treatment
Time frame: 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU d'Amiens - Hôpital Sud
Amiens, France
RECRUITINGCHU Angers
Angers, France
RECRUITINGCHRU Besançon - Hôpital Minjoz
Besançon, France
RECRUITINGCHU de Brest - Hôpital du Morvan
Brest, France
RECRUITINGInstitut d'Hématologie de Basse Normandie
Caen, France
RECRUITINGCHU d'Estaing
Clermont-Ferrand, France
RECRUITINGAPHP - Hôpital Henri Mondor
Créteil, France
RECRUITINGCHU de Dijon
Dijon, France
RECRUITINGCHU de Grenoble
La Tronche, France
RECRUITINGCHRU de Lille - Hôpital Claude Hurriez
Lille, France
RECRUITING...and 26 more locations